Cancer Research includes companies working on scientific research aimed at understanding the causes, prevention, diagnosis, treatment, and potential cures for cancer. It includes many disciplines, from biology and genetics, to clinical trials and drug development, with the ultimate goal of improving cancer care and outcomes. Cancer research companies are developing life-saving treatments and diagnostics for a growing market in high demand. These companies constantly innovate, have a global reach, and form important strategic partnerships, which makes them appealing to investors looking for profits and supporting health progress.
Analysts Offer Insights on Healthcare Companies: Certara (CERT), Exact Sciences (EXAS) and AbCellera Biologics (ABCL)
Canadian Investment Banking Group: Maintaining the Exact Sciences (EXAS.US) rating, adjusted from a buy rating to a buy rating, and the target price was adjusted from $90.00 to $85.00.
Exact Sciences Analyst Ratings
Citigroup Maintains Buy on Exact Sciences, Lowers Price Target to $80
Analysts' Top Healthcare Picks: US Physical Therapy (USPH), Exact Sciences (EXAS)
Buy Rating Affirmed for Exact Sciences on Strong Performance and Promising Growth Initiatives
Buy Rating Affirmed for Exact Sciences Amidst Strong Growth and Innovative Pipeline
Redburn Atlantic Adjusts Price Target on Biogen to $235 From $275, Keeps Neutral Rating
Analysts Offer Insights on Healthcare Companies: Lyra Therapeutics (LYRA), Bristol-Myers Squibb (BMY) and Axsome Therapeutics (AXSM)
Blueprint Medicines Analyst Ratings
Goldman Sachs: Maintains Blueprint Medicines (BPMC.US) rating, adjusted from buy to buy rating, and adjusted target price from $121.00 to $168.00.
Goldman Sachs Maintains Buy on Blueprint Medicines, Raises Price Target to $168
Leerink Upgrades Blueprint Medicines to Market Perform, Price Target at $97
Big Bank Ratings | Damo: Raising Pfizer's target price to $29 and is cautiously optimistic about this year's outlook
HC Wainwright & Co. : The Blueprint Medicines (BPMC.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $125.00 to $135.00.
Blueprint Medicines Analyst Ratings
JMP Securities Maintains Market Outperform on Blueprint Medicines, Raises Price Target to $125
Biogen Analyst Ratings
HSBC Adjusts Price Target on Biogen to $342 From $339, Maintains Buy Rating
Wells Fargo Remains a Buy on Blueprint Medicines (BPMC)